165 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to Oruka. Under the Paragon Option Agreements … the antibodies and products directed to the selected target(s) (each, an “Option”). From time to time, Oruka can choose to add additional targets
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
-17F (“IL-17A/F”) for the treatment of PsO, psoriatic arthritis (“PsA”), and other conditions. These programs each bind their respective targets … directed against certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL-23 (“ORKA
8-K
EX-99.3
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company … . The Option Agreements includes two selected targets, IL-23 (ORKA-001) and IL-17 A/F (ORKA-002). Under the Option Agreements, the Company has
425
q3p8c0c
9 Aug 24
Business combination disclosure
8:35am
425
009ck 9hz
3 Apr 24
Business combination disclosure
7:33am
8-K
EX-99.1
7qt z3516
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am